

21 September 2026

BluGlass to collaborate with global photonics leader Coherent on novel GaN device

Highlights

- BluGlass has entered into an early-stage collaboration with global photonics leader Coherent to co-develop a novel GaN-based device
- The A\$286k collaboration combines BluGlass' advanced GaN epitaxy and laser manufacturing expertise with Coherent's extensive photonics engineering and commercialisation capabilities
- The jointly developed device is being designed to address emerging scientific and medical applications requiring high-performance visible-wavelength laser technology

Global semiconductor developer BluGlass Limited (**ASX: BLG**, "BluGlass" or "Company") has entered into an early-stage collaboration with global photonics leader Coherent Corp (NYSE: COHR) to co-develop a novel gallium nitride (GaN)-based device targeting scientific and medical markets. This initial feasibility study is expected to run for three to five months and will evaluate the compatibility of the companies' proprietary processes.

Valued at ~A\$286k (US\$200k), the collaboration combines BluGlass' complementary expertise in proprietary GaN epitaxial growth and semiconductor laser development with Coherent's leadership in photonics, advanced manufacturing, and market access.

Under the agreement, the companies will jointly evaluate device architectures and manufacturing techniques to enable high-performance visible wavelength lasers for demanding scientific instrumentation and medical applications. Initial development discussions have commenced, including device architecture options, epitaxial structure designs, and process integration.

BluGlass CEO Jim Haden said, "Coherent's decision to collaborate with BluGlass is a strong vote of confidence in our GaN epitaxy and laser capabilities, reinforcing our growing industry reputation for developing differentiated technology solutions to support next-generation applications.

"While the initial phase of this collaboration focuses on advancing a novel device architecture, it has the longer-term potential to address high-value opportunities in scientific and medical applications. The collaboration with this industry leader expands our GaN laser portfolio and, more importantly, extends our reach into key scientific and medical markets that demand precision photonic performance."

This announcement has been approved for release by the Board of BluGlass.

For more information, please contact:

James Lennon, Automic Markets | +61 498 209 019 | james.lennon@automicgroup.com.au
Samuel Samhan, BluGlass CFO | ssamhan@bluglass.com

About BluGlass

BluGlass Limited (ASX:BLG) is a leading supplier of GaN laser diode products to the global photonics industry, focused on the industrial, defence, bio-medical, and scientific markets.

Listed on the ASX, BluGlass is one of just a handful of end-to-end GaN laser manufacturers globally. Its operations in Australia and the USA offer cutting-edge, custom laser diode development and manufacturing, from small-batch custom lasers to medium and high-volume off-the-shelf products.

The Company combines its proprietary low temperature, low hydrogen, remote plasma chemical vapour deposition (RPCVD) manufacturing process with advanced device design and fabrication to deliver differentiated laser solutions. With end-to-end capabilities spanning epitaxy, device design, fabrication, and testing, BluGlass is well-positioned to support critical next-generation photonics applications and sovereign supply chains.

About Coherent

Coherent (NYSE: COHR) is a global leader in harnessing light particles to transmit, process, and measure data efficiently at high speeds. Its vertically integrated technology platform enables it to partner with industry participants across data centres, communications, and industrial markets to help them facilitate their own innovation and growth. Founded in 1971 and operating in more than 20 countries, Coherent brings the industry's broadest, deepest technology stack; unmatched supply chain resilience; and global scale to help its customers solve their toughest technology challenges.